Long-Term Follow-Up Still Shows Tafinlar/Mekinist Benefit in Melanoma
Source: CureToday, June 2024
Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma.
Tafinlar (dabrafenib) plus Mekinist (trametinib) continued to be efficacious in the postsurgical treatment of patients with stage 3 melanoma, according to eight-plus years of follow-up from the COMBI-AD clinical trial.
Results of the final analysis, which were presented at the 2024 ASCO Annual Meeting and published in The New England Journal of Medicine, showed that, at eight years, the overall survival (OS; time from treatment until death of any cause) rate with the combination (438 patients) was 71% compared with 65% in those who received placebo, which is an inactive drug (432 patients).